Literature DB >> 8405020

Frequency of S-mephenytoin hydroxylation deficiency in 373 Spanish subjects compared to other Caucasian populations.

J Reviriego1, L Bertilsson, J A Carrillo, A Llerena, M J Valdivielso, J Benítez.   

Abstract

We have investigated the prevalence of poor metabolisers (PM) of S-mephenytoin in 373 unrelated, healthy Spanish Caucasian subjects, based on the enantiomeric S/R mephenytoin ratio in urine collected 0-8 h and 24-32 h after intake of the racemic drug. Five of the subjects were PM (1.34%, 95% confidence interval 0.18-2.59%), a prevalence lower than in 6 other Caucasian populations, but only significantly lower than in studies in France and Switzerland (P < 0.01). We suggest that this difference might be due to the use of different phenotyping procedures.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8405020     DOI: 10.1007/bf02440867

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  24 in total

1.  Slow omeprazole metabolizers are also poor S-mephenytoin hydroxylators.

Authors:  T Andersson; C G Regårdh; M L Dahl-Puustinen; L Bertilsson
Journal:  Ther Drug Monit       Date:  1990-07       Impact factor: 3.681

2.  Phenotyping polymorphic drug metabolism in the French Caucasian population.

Authors:  E Jacqz; H Dulac; H Mathieu
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

3.  Hydroxylation polymorphisms of debrisoquine and mephenytoin in European populations.

Authors:  G Alván; P Bechtel; L Iselius; U Gundert-Remy
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

4.  S-mephenytoin hydroxylation phenotypes in a Swedish population determined after coadministration with debrisoquin.

Authors:  E J Sanz; T Villén; C Alm; L Bertilsson
Journal:  Clin Pharmacol Ther       Date:  1989-05       Impact factor: 6.875

5.  Direct enantiomeric resolution of mephenytoin and its N-demethylated metabolite in plasma and blood using chiral capillary gas chromatography.

Authors:  P J Wedlund; B J Sweetman; C B McAllister; R A Branch; G R Wilkinson
Journal:  J Chromatogr       Date:  1984-04-13

6.  Separation of human liver microsomal tolbutamide hydroxylase and (S)-mephenytoin 4'-hydroxylase cytochrome P-450 enzymes.

Authors:  P K Srivastava; C H Yun; P H Beaune; C Ged; F P Guengerich
Journal:  Mol Pharmacol       Date:  1991-07       Impact factor: 4.436

7.  The mephenytoin oxidation polymorphism is partially responsible for the N-demethylation of imipramine.

Authors:  E Skjelbo; K Brøsen; J Hallas; L F Gram
Journal:  Clin Pharmacol Ther       Date:  1991-01       Impact factor: 6.875

8.  The activation of the biguanide antimalarial proguanil co-segregates with the mephenytoin oxidation polymorphism--a panel study.

Authors:  S A Ward; N A Helsby; E Skjelbo; K Brøsen; L F Gram; A M Breckenridge
Journal:  Br J Clin Pharmacol       Date:  1991-06       Impact factor: 4.335

9.  Importance of genetic factors in the regulation of diazepam metabolism: relationship to S-mephenytoin, but not debrisoquin, hydroxylation phenotype.

Authors:  L Bertilsson; T K Henthorn; E Sanz; G Tybring; J Säwe; T Villén
Journal:  Clin Pharmacol Ther       Date:  1989-04       Impact factor: 6.875

10.  Phenotypic differences in mephenytoin pharmacokinetics in normal subjects.

Authors:  P J Wedlund; W S Aslanian; E Jacqz; C B McAllister; R A Branch; G R Wilkinson
Journal:  J Pharmacol Exp Ther       Date:  1985-09       Impact factor: 4.030

View more
  5 in total

Review 1.  Interethnic variation of CYP2C19 alleles, 'predicted' phenotypes and 'measured' metabolic phenotypes across world populations.

Authors:  I Fricke-Galindo; C Céspedes-Garro; F Rodrigues-Soares; M E G Naranjo; Á Delgado; F de Andrés; M López-López; E Peñas-Lledó; A LLerena
Journal:  Pharmacogenomics J       Date:  2015-10-27       Impact factor: 3.550

Review 2.  Interethnic differences in drug metabolism: influence of genetic and environmental factors on debrisoquine hydroxylation phenotype.

Authors:  A Llerena; J Cobaleda; C Martínez; J Benítez
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1996 Apr-Jun       Impact factor: 2.441

3.  Comparison of (S)-mephenytoin and proguanil oxidation in vitro: contribution of several CYP isoforms.

Authors:  J K Coller; A A Somogyi; F Bochner
Journal:  Br J Clin Pharmacol       Date:  1999-08       Impact factor: 4.335

4.  Genetic polymorphism of (S)-mephenytoin 4'-hydroxylation in populations of African descent.

Authors:  H G Xie; R B Kim; C M Stein; G R Wilkinson; A J Wood
Journal:  Br J Clin Pharmacol       Date:  1999-09       Impact factor: 4.335

Review 5.  Clinical significance of the cytochrome P450 2C19 genetic polymorphism.

Authors:  Zeruesenay Desta; Xiaojiong Zhao; Jae-Gook Shin; David A Flockhart
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.